𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Correction: “Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review”

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
45 KB
Volume
54
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

In the June 2011 issue of HEPATOLOGY, in the article entitled ''Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review'' (volume 53, pages 2121-2129) the data in Tables 2 and3 are to be corrected as listed below:

On page 2124, under the heading ''Predicting responses to IFN-based therapy with HBsAg Levels'', the percentages in the first sentence are 35 and 25, respectively:

Because a sustained response to pegylated interferon (PEG-IFN) is achieved in only approximately 35% of HBeAg-positive patients and 25% of HBeAg-negative patients, identifying a potential treatment success is valuable for both the patient and the physician. A number of groups have retrospectively analyzed response rates in PEG-IFN cohorts with respect to on-treatment HBsAg declines.

📜 SIMILAR VOLUMES

Clinical utility of hepatitis B surface
Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review
✍ Yun-Fan Liaw 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

This clinically relevant review focuses on recent findings concerning hepatitis B surface antigen (HBsAg) quantitation in untreated patients and treated patients with chronic hepatitis B. Recent studies and emerging data have shown that both HBsAg and hepatitis B virus (HBV) DNA levels decline durin

Clinical utility of hepatitis B surface
Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review
✍ Yun-Fan Liaw 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views

This clinically relevant review focuses on recent findings concerning hepatitis B surface antigen (HBsAg) quantitation in untreated patients and treated patients with chronic hepatitis B. Recent studies and emerging data have shown that both HBsAg and hepatitis B virus (HBV) DNA levels decline durin

Association of concurrent hepatitis B su
Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection
✍ Ji Sun Jang; Hyoung Su Kim; Ha Jung Kim; Woon Geon Shin; Kyung Ho Kim; Jin Heon 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 2 views

## Abstract Antibody to hepatitis B surface antigen (HBsAg) (anti‐HBs) can exist in patients with chronic hepatitis B virus (HBV) infection. To date, little is known about the association of concurrent HBsAg and anti‐HBs (concurrent HBsAg/ anti‐HBs) with hepatocellular carcinoma (HCC). The aim of t

Correlation of serum hepatitis B surface
Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B
✍ Myoung Hee Lee; Da Mi Lee; Soon Sun Kim; Jae Youn Cheong; Sung Won Cho 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract Recent studies have suggested that quantifying the serum HBsAg levels can predict the response to pegylated interferon. We aimed to determine the change in serum HBsAg levels during entecavir (ETV) treatment and the correlation with treatment response in chronic HBeAg‐positive and HBeAg

Characterization of viral kinetics in pa
Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B
✍ I-Chin Wu; Nan-Haw Chow; Pin-Nan Cheng; Wen-Chun Liu; Kung-Chia Young; Wei-Lun C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract A study was conducted during a 1 year follow‐up to characterize the viral kinetics in hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B and to develop a model of predicting the probability of spontaneous HBeAg seroconversion. Fifty‐seven patients with HBeAg‐positive chronic hep

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60